<DOC>
	<DOCNO>NCT00992563</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , effect investigational drug AL-39324 treatment wet AMD .</brief_summary>
	<brief_title>WALTZ - Wet Age-Related Macular Degeneration ( AMD ) AL-39324 Treatment Examination</brief_title>
	<detailed_description>Following single administration , patient follow 6 month postinjection .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Willing give write informed consent , make require study visit follow instruction ; The study eye : must primary diagnosis choroidal neovascularization ( CNV ) secondary AMD ; lesion must large 30 mm2 ; must edema measure great 340 Î¼m ; must visual score 73 34 letter , inclusive ; must able clear picture take back eye ; Other protocoldefined inclusion criterion may apply . The study eye must treat exudative AMD previously ; The study eye must ocular disease , condition , infection , recent surgery would interfere vision examination back eye ; The study eye must uncontrolled glaucoma ; The study eye must miss lens ; Must take medication toxic lens ; Must take oral ocular corticosteroid ; Must unstable progressive condition would interfere study visit ; Must allergy component test article sensitivity fluorescein dye ; If female , must pregnant nursing must agree adequate birth control ; Must participate another drug device study within 30 day screen study ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>wet age-related macular degeneration , exudative</keyword>
</DOC>